Labcorp To Pay Up To $872M For BioReference Health Assets, Including 4Kscore Prostate Test

Labcorp will pay up to $872 million in a deal to acquire BioReference Health's labs, over 80 patient service centers, and the FDA-approved 4Kscore prostate cancer test from OPKO Health, allowing OPKO to focus on its biopharmaceutical business.

This Wire brief sits within Fusion42's coverage of Medtech.